Recently, in a piece in the Economic Times, in context of the tragedy in The Gambia, @preddy85 and I discussed the importance of a recall law aimed at withdrawing adulterated or dangerous drugs from the market. 1/n
2/n
An essential feature of this is the framing and formulating of a robust drug recall law.
While our government has a system in place for testing drug samples already on the market to assess their quality, there is no system today to mandatorily recall a drug that has
3/n been declared as “Not of Standard Quality” or NSQ by a Govt. Laboratory.
This is a huge issue in a country like India with 37 different regulators who cannot operate outside their respective jurisdictions.
4/n Consider this:
In August 2020, a 2 year old child from Baddi died allegedly due to the consumption of a DEG adulterated cough syrup manufactured by the same company whose cough syrup was responsible for the deaths of the 11 children from Jammu just 8 months earlier.
It is likely that the same batch of adulterated ingredients was used to manufacture different brands of cough syrups which were not effectively recalled the first time when 11 children died earlier.
6/n The adulteration and the erring manufacturer were reported to @CDSCO_INDIA_INF, asking for urgent
steps to remove this product from pharmacy shelves.
So why then did a 2 year old have to die 8 months later under similar circumstances?
7/n This is how the DCGI responded:
It issued a letter to the drug controllers of States and Union Territories to take necessary action and appropriate steps for stopping the sale and distribution of Cofset AT syrup in the country.
8/n Left to themselves, we know that pharma manufacturers will never withdraw their drugs voluntarily because recalls ruins their reputation and creates liability issues for them.
The government knows this very well.
9/n Yet, India does not have a drug recall law— and the reason as to why it lacks such a law is a story of epic bureaucratic procrastination and regulatory capture.
This is the 2nd thread on "Regulatory Capture" - the first one from a couple of weeks ago is here 👇
11/n Before narrating the story of how we have arrived here, lets first understand why a Recall Law is necessary.
Even well formulated drugs degrade over time. That is why we have a shelf-life and expiration date. Sometimes, batch release does not catch everything may go wrong.
12/n In such cases, we need a framework and a process by which we can recall the entire product in the market so that it doesn’t continue to harm people.
Not all recalls are urgent. For example, the @US_FDA guideline says Class I recalls are those that cause immediate harm
13/n to patients, while Class III recalls are usually for mislabeling.
In the US, the manufacturer is responsible for the recall while the regulator oversees the company’s strategy, assess the adequacy of the recall process.
This approach will not work for us where we have
14/n 38 regulators, one for each state and the central regulator, the @CDSCO_INDIA_INF
Back to the story: 1976: In a meeting of the Drugs Consultative Committee (DCC), all state drug controllers, the DCGI, and representatives from the @MoHFW_INDIA came together
15/n “to review the existing procedure of recall by manufacturers of drugs found deficient”.
16/n It was resolved that the Drug controller of the State where the mfg. was located would be responsible for gathering information from all the distributors & then transmitting those details to the other State drug controllers in whose jurisdiction the distributor was located.
17/n Unfortunately, this decision was never translated into law via an amendment to either the Drugs and Cosmetics Act 1940 or the Drugs and Cosmetics Rules 1945.
In effect, the issue of recall was left entirely to the individual discretion of state drug controllers.
18/n 1989: 26th meeting of the DCC.
The Secretary of Health and Family Welfare expressed his concern about the recall of drugs found to be hazardous to public health.
He wanted in place a mechanism to ensure complete recalls of such drugs in a span of 72 hours.
19/n The minutes of the meeting record that a high-powered group under the Chairmanship of the Health Minister of Maharashtra had been constituted by the Central Council of Health to make recommendations on many issues.
We do not know what became of these recommendations.
21/n 1996: In a meeting of the DTAB (Drugs Technical Advisory Board)
Agenda: To ensure the swift recall of spurious or adulterated drugs, within the shortest time frame.
What followed was a perversion that would perhaps embarrass even the most cynical of bureaucrats.
22/n Simply put, it was concluded that it would be too inconvenient for the industry & the bureaucracy if the law mandated mechanisms to ensure the recall of NSQ drugs within a period of 48 hrs, despite it being known that NSQ drugs pose a grave threat to public health.
23/n 2004: 35th meeting of the DCC.
The matter was sent to a sub-committee for a detailed discussion.
Given that there is no mention of this sub-committee in future meetings of the DCC, it is safe to presume that the it never submitted its report. 🤷♂️
24/n 2011: 43rd meeting of the DCC.
When the issue of time sensitive recalls of NSQ drugs came up once again, the DCC came to this conclusion:
25/n And so, yet another sub-committee was set up to look into the very same issue.
Its recommendations were never discussed in future meetings of the DCC, possibly because it never submitted its report.
26/n 2012: 59th Report of the Parliamentary Standing Committee on Health and Welfare:
“... There is no effective method of recalling unsold stocks lying in the distribution network. This cannot be allowed to go on…” (contd.) 👇🏼
27/n “...once a batch of [substandard] drug is…reported to CDSCO, it should issue a press release forthwith & even insert paid ads in the newspapers apart from uploading the information on its website.
Retail chemists should be advised to…return them to local Drugs Inspectors.”
28/n The CDSCO then came out with recall guidelines to satisfy the Parliamentary committee: cdsco.gov.in/opencms/export…
Not surprisingly, the Ministry simply omitted mentioning to the Parliament the crucial detail that those recall guidelines lacked the force of law
29/n and were hence not binding on any governmental authority.
The guidelines were very poorly drafted and are quite vague on fixing responsibilities.
For e.g., on the issue of “inter-State” recalls, it merely states:
“For inter-State coordination & communication, the zonal
30/n offices of CDSCO of their respective jurisdiction are responsible.”
What happens when drug controllers of different states disagree with each other on recalls?
What does it mean to say that the CDSCO is responsible for “interstate co-ordination and communication”
31/n when the CDSCO has no administrative authority over state drug controllers?
2016: 50th meeting of the DCC
A two pronged strategy was proposed:
1) To amend the rules and create a legally binding framework for recall.
32/n 2) All States to display information about their NSQ drugs on the “SUGAM” portal (an e-governance platform developed for drug controllers).
These were sensible recommendations, yet nothing was translated into the law. 🤷♂️
33/n And so we come to the last iteration of this "masterly inactivity"
2019: 57th meeting of the DCC: A sub-committee of DCC submitted a report on the issue but still no rules were enacted
34/n As a result, 46 years after the issue of recalls was first raised at the DCC meeting in 1976, India still lacks a robust law on recalling NSQ drugs.
What does this say about our drug regulator’s attitude towards protecting public health?
35/n This, despite thousands of NSQ drugs being detected every year by government laboratories across India.
Some of them with dangerous impurities ranging from bacterial endotoxins and glass particles, which have a direct adverse consequences to patients.
36/n @preddy85 and I lay this our in great detail in our book, ‘The #TruthPill: The Myth of Drug Regulation in India’.
Recently, the Uttarakhand State Government issued a ban and subsequently revoked its order prohibiting Patanjali Ayurved from manufacturing five products to treat blood pressure, diabeties, glaucoma and other diseases.
As @Preddy85 and I were about to begin the session for the launch of the #truthpill this past Saturday evening, like clockwork, we received an email from the @CDSCO_INDIA_INF with a menacing notice threatening
1/n
2/n “to exhaust every available recourse including all possible legal options to take action to dissuade us” from repeating certain comments we made in our interview published in the India Today Interview: indiatoday.in/india/story/ki…
Want to know what regulatory capture looks like? Read on...
One of the drugs that the Parliamentary Standing Committee in its 59th Report reviewed was the FDC of Flupentixol and Melitracen used to treat depression. @Preddy85@truthpill
1/n
This combination does not exist in any developed markets. The Parliamentary Standing Committee asked for a copy of the approval files from the @CDSCO_INDIA_INF.
This is what it said in its report:
3/n
Responding to this finding of the PSC, the @MoHFW_INDIA constituted a committee to investigate and report on this questionable drug approval under the leadership of Prof T M Mohapatra:
How did this firm generate six-month real time accelerated stability data when the inspection found no samples of the product in the stability chamber?
One of key requirements for product registration is for the manufacturer to show that its formulation is stable under
Quick follow up thread on the #coughsyrup tragedy in The Gambia.
The official line seems to be that we dont have to worry about adulterated cough syrup because the company is making this product just for its overseas customers.
Lets see if this holds water, shall we?
1/n
2/n Here is a snapshot of the company's catalog showing the line of cough syrups it manufactures:
3/n While they may not selling cough syrup under the names they exported it to the Gambia, they are likely selling cough-syrup in India.
Here are some of their products – we found domestic trademark registrations for Kof-Total which likely means they are selling it in India: